Drug intelligence / Profile preview

Ster

Development stage: Unknown
Lead developer: Union Chemicals
Modality: Small Molecules
Administration: Ophthalmic

Overview

Ster is an ophthalmic suspension containing 1% prednisolone, a corticosteroid. It is indicated for the control of postoperative inflammation, specifically following cataract surgery. The drug is developed by Union Chemicals.

Brand names: Ster

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on Ster.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ster.

Explore the full profile